MS 5

Question 1

Medications for MS do this:

Answer 1

• modify disease course
• treat attacks
• manage symptoms

Question 2

How many disease-modifying agents approved by the FDA?

Answer 2

14

Question 3

Types of disease-modifying agents that can be used to treat MS

Answer 3

• self-injectables
• oral
• IV

Question 4

How many self-injectables are available to treat MS?

Answer 4

8

Question 5

How many oral drugs are available to treat MS?

Answer 5

3

Question 6

How many IV drugs are available to treat MS?

Answer 6

3

Question 7

Drug type: Natalizumab (Tysabri)

Answer 7

IV

Question 8

Drug type: Teriflunomide (Aubagio)

Answer 8

Oral

Question 9

Drug type: Fingolimod (Gilenya)

Answer 9

Oral

Question 10

Drug type: Interferon beta 1-a (Avonex and Rebif)

Answer 10

Self-injectable

Question 11

Drug type: Interferon beta 1-b (Betaseron and Extavia)

Answer 11

Self-injectable

Question 12

Drug type: Daclizumab (Zinbryta)

Answer 12

Self-injectable

Question 13

Drug type: Dimethyl fumarate (Tecfidera)

Answer 13

Oral

Question 14

Drug type: Mitoxantrone (Novantrone)

Answer 14

IV

Question 15

Drug type: Glatiramer acetate (Copaxone and Glatopa)

Answer 15

Self-injectable

Question 16

Drug type: Peginterferon beta 1-a (Plegridy)

Answer 16

Self-injectable

Question 17

Drug type: Alemtuzumab (Lemtrada)

Answer 17

IV

Question 18

Why is early tx so early with MS?

Answer 18

Neuroinflammation and neurodegeneration occur early in the disease course

Question 19

Individuals with first clinical event with MRI findings consistent with MS have:

Answer 19

high probability of further disease activity

Question 20

Significance of early disease activity

Answer 20

Likely impacts long-term disability

Question 21

What types of cognitive/emotional changes occur early on in MS?

Answer 21

• cognitive changes
• depression
• fatigue

Question 22

Impact of tx following first clinical event

Answer 22

• Delay conversion to definite MS

- Reduce brain atrophy and disability worsening

Question 23

Why does tx need to be ongoing for MS?

Answer 23

• once tx is initiated, it needs to be ongoing for benefits to continue
• cessation negatively impacts outcomes
• relapse rates can return to baseline if tx is interrupted

Question 24

What happens to FSS and EDSS scores if tx is stopped and relapse rates return to baseline?

Answer 24

both increase

Question 25

rationale for access to full range of tx options: use of interferon beta and natalizumab

Answer 25

- frequently associated with development of neutralizing antibodies - reduces clinical efficacy

Question 26

rationale for access to full range of tx options: contraindications, nonresponders

Answer 26

need access to options

Question 27

rationale for access to full range of tx options: severity of disease

Answer 27

- varies at onset | - some experience early aggressive disease

Question 28

rationale for access to full range of tx options: African Americans

Answer 28

Some have more active disease

Question 29

rationale for access to full range of tx options: adherence

Answer 29

Some people don't adhere to tx regimen and need access to options